Prota, Chr. Hansen partner on peanut allergy

25 Apr 2018

Prota Therapeutics has partnered with Chr. Hansen to assess what is said to be the world’s best documented probiotic strain, LGG, in a Phase III clinical trial to develop a treatment for peanut allergy.

Prota, Chr. Hansen partner on peanut allergy

Prota Therapeutics, the developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen. The partnership will assess what is said to be the world’s best documented probiotic strain, LGG, in a Phase III clinical trial to develop a treatment for peanut allergy.

Approximately 220-250 million people globally suffer from food allergies, an increase of 350% over the past 20 years. The economic impact for treatment of food allergies in the US has been estimated at US$24.8 billion per year.

Peanut allergy is the most common cause of anaphylaxis, a life-threatening allergic reaction, and one of the most common causes of death from food allergy2. More than 3 million Americans suffer from peanut allergy resulting in a global peanut allergy therapeutics market estimated to reach more than US$10 billion by 2025.

Prota Therapeutics says it is pioneering a new form of oral immunotherapy treatment. It combines Chr. Hansen’s specifically formulated LGG4 probiotic strain, Lactobacillus rhamnosus, with targeted doses of proprietary formulations of peanut protein. The treatment is designed to reprogram the immune system’s response to peanuts and eventually develop tolerance.

Building upon earlier trials conducted at the Murdoch Children’s Research Institute, Prota Therapeutics says it is progressing towards a large-scale Phase III clinical trial, under a US Investigational New Drug Application (IND). The aim is to commercialize a medicinal product using a new pharmaceutical grade therapeutic dosage form for treating peanut allergy, and to explore indications for treating other food allergies.

"An effective therapy to treat peanut allergies is now a realistic target. Chr. Hansen is the ideal partner for us in this next step, both as the owner of one of the key components in the therapeutic product – LGG – and as a leading expert in microbial solutions. Chr. Hansen has demonstrated the capability to deliver a pharmaceutical quality product that can be regulated as a biological therapeutic product. Together with our proprietary peanut protein formulation, we aim to progress this through to commercialization of a treatment for peanut allergies,” said Dr. Suzanne Lipe, CEO at Prota Therapeutics.

Numerous studies have highlighted the therapeutic potential of specific bacteria in preventing and treating metabolic, gastrointestinal and other diseases. Investigating specific bacteria for the treatment of food allergies is an area that has recently gained momentum.

Having produced LGG for more than 10 years before fully acquiring LGG from Valio in 2016, this new partnership is an example of how Chr. Hansen’s focus on industry leading product quality and clinical documentation can expand the potential of the LGG probiotic strain into a new breakthrough area.

Christian Barker, Executive Vice President, Health & Nutrition at Chr. Hansen, said: “Chr. Hansen has the ability to maximize the value of a probiotic strain through our deep experience in microbial process development and formulation, our focus on quality, and our global reach. The partnership with Prota Therapeutics is part of our strategy to become the partner of choice for companies wanting to develop new generations of therapeutic microbes.”

Find out more about Chr. Hansen

Related categories

Related tags

Innovation Natural

Related news

Harnessing oat hulls to make sustainable sweeteners

Harnessing oat hulls to make sustainable sweeteners

30 Jun 2022

Finnish company Fazer is transforming the oat hull side streams from its existing oat mill into the low-calorie sweetener, xylitol.

Read more 
Parmesan partnership to put ‘blockchain ready’ digital chip on all cheese wheels

Parmesan partnership to put ‘blockchain ready’ digital chip on all cheese wheels

29 Jun 2022

A new line of food-safe and secure digital labels on each Parmigiano Reggiano cheese wheel will deliver previously unseen levels of traceability, product control, and quality assurance, says the Consorzio del Parmigiano Reggiano (CFPR).

Read more 
‘Game-changing’ tech such as automation and synthetic biotechnology the future for manufacturing, VTT predicts

‘Game-changing’ tech such as automation and synthetic biotechnology the future for manufacturing, VTT predicts

28 Jun 2022

“Game-changing technologies” such as synthetic biotechnology – combining engineering principles with biology in natural production processes – and more automation could revolutionise European food manufacturing, as well as for a host of other sectors i...

Read more 
World first: Dutch team develop method to extract high-value protein from tomato leaf

World first: Dutch team develop method to extract high-value protein from tomato leaf

27 Jun 2022

Tomato leaves that are currently seen as a major waste stream in horticulture could provide a reliable and sustainable source of rubisco – a widespread plant protein that has potential in food and drink, say researchers.

Read more 
Boom or bust: Are consumers ready for the alternative protein revolution?

Boom or bust: Are consumers ready for the alternative protein revolution?

24 Jun 2022

While excitement over alt-proteins is high among industry and investors, major challenges remain for companies looking to convince consumers to switch to a plant-based ‘meat alternative’.

Read more 
Mars launches animal-free chocolate with Perfect Day’s whey protein

Mars launches animal-free chocolate with Perfect Day’s whey protein

21 Jun 2022

Mars has launched a vegan chocolate bar made with biotech unicorn Perfect Day’s animal-free whey protein made via precision fermentation.

Read more 
Unilever in $120m biotech venture to scale palm oil alternative

Unilever in $120m biotech venture to scale palm oil alternative

20 Jun 2022

Unilever has teamed up with US biotech company Genomatica to commercialise its palm oil alternative produced via a biotechnology fermentation process.

Read more 
Clutch Cognition creates functional drinks with brain health botanicals

Clutch Cognition creates functional drinks with brain health botanicals

7 Jun 2022

Danish startup, Clutch Cognition, has entered the functional drinks space targeting cognitive health with a blend of botanicals and plant-based ingredients such as sage, green oat, green tea, and guar beans.

Read more 
Future-proof chocolate from Voyage Foods

Future-proof chocolate from Voyage Foods

30 May 2022

Chocolate made without cacao, peanut butter without peanuts, coffee without the beans. All these futuristic-sounding possibilities have become a reality with Voyage Foods’ reverse engineering technology that recreates these popular foods using ot...

Read more 
Pet food space gets healthy infusion at Nestlé's latest accelerator class

Pet food space gets healthy infusion at Nestlé's latest accelerator class

18 May 2022

Pets and the food they eat is beginning to reflect the dietary choices that their owners themselves are making. From obesity-fighting formulations to the introduction of ancient grains and alternative proteins, the options for targeted, functional food...

Read more